Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of IBI323 in Participants With Advanced Malignancies

Next Previous
X
Search
Trial Profile

A Phase I, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of IBI323 in Participants With Advanced Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Sep 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IBI 323 (Primary)
  • Indications Advanced breast cancer; Carcinoma; Gastric cancer; Head and neck cancer; Liver cancer; Mesothelioma; Nasopharyngeal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Oesophageal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Innovent Biologics

    • Most Recent Events

    • 14 Sep 2022 Planned End Date changed from 9 Mar 2023 to 9 Dec 2023.
    • 14 Sep 2022 Planned primary completion date changed from 23 Jun 2022 to 23 Jun 2023.
    • 11 Jul 2021 Status changed from not yet recruiting to recruiting, according to an Innovent Biologics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top